Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL).

Background: ALL is the most frequent hematological tumor in children, so during remission induction chemotherapy protocol (RICP) adverse events (AEs) may appear. The public program in Mexico in charge of financial support to oncologic children without social security delivered a fix amount for ALL chemotherapy, but additional money needed to treat any other unexpected condition should be taken from the budget of the oncologic healthcare providers. So the purpose of our study was to estimate and evaluate the direct medical costs associated to EAs during RICP in children with ALL.

Economic issues of Severe Acute Respiratory Infections for influenza in Mexican children attended in a tertiary public hospital.

Background: Influenza cause a clinical and economic burden for health systems and society. It is necessary to know the cost of the disease in order to perform cost-effectiveness assessments of preventive or treatment interventions.

Objective: Assess the costs of the care of children with influenza in a third level hospital in Mexico.